BD Phoenix™ Panels
BD Phoenix™ panels support true MICs and broad breakpoint coverage, helping clinicians obtain accurate data from every test.
- Overview
- Applications
- Products & Accessories
- EIFU & Resources
BD Phoenix™ panels, when used with the BD Phoenix™ M50, provide timely and accurate identification and susceptibility results for most clinically significant aerobic and facultative anaerobic Gram-negative and Gram-positive bacteria, as well as identification of yeast and yeast-like organisms.1-6
BD Phoenix™ panels require no refrigeration, are leak resistant, and are available in a variety of formats including identification-only, susceptibility-only, and combination of identification and susceptibility panels, for use with the BD Phoenix™ M50 Automated ID/AST Solution.
BD Phoenix™ Panel brochure
BD Phoenix™ M50 Panels are designed to maximize clinical microbiology laboratory productivity and help strengthen your defense against antimicrobial resistance
- BD Phoenix™ Emerge™ panel offers extended antimicrobial ranges aligned with current recognized breakpoints
- Broadest menu of antibiotics per panel with maximized drug bug coverage
- Ample well space for expanded antimicrobials
- Room temperature storage
- True minimum inhibitory concentration from dilutions using doubling antibiotic concentrations
- Closed leak-resistant panels
Every well counts and every well contributes to higher accuracy
BD Phoenix™ panels support true MICs and broad breakpoint coverage, helping clinicians obtain accurate data from every test
- 136-well design provides the highest analytical throughput per panel enabling true doubling dilutions and precise MIC determination compared to other commercial systems
- Optimized well layout accommodates a broad selection of clinically relevant antimicrobials heling to reduce the need for offline testing
- Ensures critical concentrations are included to detect resistance at or near clinical breakpoints
- Layout allows for updates as resistance patterns and guidelines evolve
The BD Phoenix™ panels are designed to help clinicians make confident, timely decisions to improve patient outcomes
Provides Flexible Panel Formats
- ID-only Panels
- Gram-positive, Gram-negative, Yeast
- 51 substrates for ID
- AST-only Panels
- Gram-positive, Gram-negative
- 85 wells for AST
- Combo Panels (ID and AST)
- Gram-positive, Gram-negative, Strep
- 51 substrates for ID
- 85 wells for AST
The BD Phoenix™ Emerge™ panels flexible design and ample well capacity reduce complexity and keep your team focused on clinical impact
BD Phoenix™ Emerge™ Panel – AST Only
- Gram-positive, Gram-negative
- 136 drug wells for AST
- Broader antimicrobial selection with extended concentration ranges for comprehensive breakpoint coverage
- Built in confirmatory resistance marker for ESBL and CPO
Detecting carbapenamase-producing organisms (CPOs)
The BD Phoenix™ CPO detect test, offered on certain Gram- negative panels, is currently the only phenotypic test on an automated AST system that provides CPO detection and Ambler classification.
This test is available in two panel configurations that allow labs to test for CPOs as part of routine susceptibility testing:
- 2-well configuration—detection of carbapemenase in Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii
- 6-well configuration—detection of carbapemenase in Enterobacterales, P. aeruginosa, and A. baumannii and Ambler classification (A, B or D) in Enterobacterales
Bloodstream Infection Solution
BD Clinical and Lab Support
BD Diagnostic Solutions is Now Waters Advanced Diagnostics
BD Diagnostic Solutions and Biosciences have combined with Waters Corporation to create a life sciences and diagnostics leader driven by innovation and a relentless commitment to our customers.
As we begin our new journey as part of Waters, there will be no immediate changes in how we serve you. The way you order your products and services and how you process payment for them will not change. Your points of contact for sales, customer service, technical service and support or clinical services will remain the same.
- The BD Phoenix™ system offers identification-only panels and combination ID/AST panels, using 51 wells for identification substrates.
- The instrument can provide rapid identification of most clinically significant Gram-negative and Gram- positive bacteria, as well as yeast.
- The BD Phoenix™ system offers 85 wells for antimicrobial dilutions on standard AST-only panels and combination ID/AST panels, and 136 wells on the BD Phoenix™ Emerge™ panel.
- The instrument can provide rapid susceptibility results for most clinically significant Gram-negative and Gram-positive bacteria.
- The BD Phoenix™ system panels test for several resistance markers*such as**:
- Gram-positive bacteria
- HLAR—High Level Aminoglycoside Resistant Enterococcus
- iMLSb—Inducible Clindamycin Resistance
- MRSA—based on Oxacillin Interpretation with Staphylococcus species
- mecA - detection in mecA-mediated resistance Staphylococcus Aureus
- BL-Staphylococcus ß-Lactamase (Nitrocefin-based test)
- VRSA—Vancomycin-Resistant Staphylococcus Aureus
- VRE—based on Vancomycin interpretation
- Gram-negative bacteria
- CPO—Carbapenemase Producing Organism
- ESBL—offered on Gram-negative panels and requires no additional disc diffusion or E-Test confirmation
- Gram-positive bacteria
* Depending on BD Phoenix™ panel type and organism identification.
- The BD Phoenix™ CPO detect test, available on certain BD Phoenix™ Gram-negative panels, provides information, including Ambler classification, to help guide clinicians in their treatment decisions.
- This test is available in two-panel configurations that allow microbiology labs to test for CPOs as part of routine susceptibility testing on BD Phoenix™ panels:
- 2-well configuration—provides detection of Carbapenemase-producing organisms in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
- 9-well configuration—provides detection of Carbapenemase-producing organisms and Ambler classification (A, B or D) in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii
- The BD Phoenix™ CPO detect test is currently the only phenotypic test on an automated AST system that provides CPO detection and Ambler classification.
- On average, the BD Phoenix™ CPO detect test detects and classifies CPOs from isolated colonies within 6 to 11 hours**.
**BD internal studies—data on file
Our collection of literature on industries and on our offerings gives you information you can use to continue striving for excellence.
We support the healthcare industry with market-leading products and services that aim to improve care while lowering costs. We host and take part in events that excel in advancing the world of health™.
The BD Learning Academy offers a centralized repository of BD product training, education, and the ability to connect courses to your LMS.
We promote clinical excellence by providing various resources on best practices, clinical innovations and industry trends in healthcare.
- BD Phoenix™ M50 Automated Microbiology System User's Manual (500008930).
- .Carey RB et al. Failure of Automated Systems to Detect Vancomycin-Resistant Staphylococcus aureus. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, 2004.
- Tenover FC et al. Emerg Infect Dis. 2006;12(8):1209–13.
- Kulah C et al. BMC Infect Dis. 2009;9:30.
- Mittman SA et al. J Clin Microbiol. 2009;47(11):3557–61.
- Woodford N et al. J Clin Microbiol. 2010;48(8):2999–3002.
Disclaimer:
This business has been acquired by Waters Corporation (“Waters”). For products referenced on this page, the legal manufacturer remains Becton, Dickinson and Company or one of its affiliates or subsidiaries (“BD”) until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under the regulatory authority of BD. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary waters.com/bdtransaction.